Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

This study is ongoing, but not recruiting participants.
Fondazione Epatocentro Ticino
Vifor Pharma
Intercept Pharmaceuticals
Information provided by (Responsible Party):
Benedetta Terziroli, MD, Fondazione Epatocentro Ticino Identifier:
First received: July 25, 2016
Last updated: February 13, 2017
Last verified: February 2017
PBC is a rare, autoimmune, cholestatic liver disease with genetic and environmental pathogenetic factors. Data about epidemiology of PBC in Switzerland are completely lacking. Epidemiology can be a powerful tool in yielding important clues as to burden and etiology of diseases. In addition, the investigators study will be the first one carried out in the country on PBC, and therefore will raise disease awareness and create a network.

Primary Biliary Cirrhosis

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Other
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 10 Years
Official Title: The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

Resource links provided by NLM:

Further study details as provided by Fondazione Epatocentro Ticino:

Primary Outcome Measures:
  • Prevalence of PBC in Switzerland [ Time Frame: from 1.1.2005 until 31.12.2015 ]

Enrollment: 501
Actual Study Start Date: December 2015
Estimated Study Completion Date: March 2017
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
PBC patients living in Switzerland

Inclusion Criteria:

  • PBC patients living in Switzerland

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02846896

Fondazione Epatocentro Ticino
Lugano, Switzerland, 6900
Sponsors and Collaborators
Benedetta Terziroli, MD
Fondazione Epatocentro Ticino
Vifor Pharma
Intercept Pharmaceuticals
  More Information

Responsible Party: Benedetta Terziroli, MD, MD, Fondazione Epatocentro Ticino Identifier: NCT02846896     History of Changes
Other Study ID Numbers: SwissPBC - SASL36
Study First Received: July 25, 2016
Last Updated: February 13, 2017

Additional relevant MeSH terms:
Liver Cirrhosis
Liver Cirrhosis, Biliary
Pathologic Processes
Liver Diseases
Digestive System Diseases
Cholestasis, Intrahepatic
Bile Duct Diseases
Biliary Tract Diseases processed this record on May 22, 2017